Genistein is under clinical development by Humanetics and currently in Phase II for Pulmonary Radiation Toxicity. According to GlobalData, Phase II drugs for Pulmonary Radiation Toxicity does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Genistein LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Genistein overview
Genistein (BIO-300) is under development as a medical radiation countermeasure for the prevention or treatment of erectile dysfunction in prostate cancer, acute radiation syndrome (ARS), idiopathic pulmonary fibrosis, radiation-induced pneumonitis, post-acute sequelae of covid 2019 (PASC or long covid), pulmonary fibrosis, decrease the incidence of mucositis, oral lesions, and salivary gland dysfunction in head and neck cancer patients and to protect healthy tissues against the damaging effects of routine CT scans and x-rays and acute respiratory distress syndrome, pulmonary fibrosis patients with coronavirus infection. The drug candidate is administered by oral route. BIO-300 is a non-synthetic single molecular agent. BIO 300 is suspension of genistein nanoparticles. Genistein is a naturally occurring chemical known as an isoflavone, derived from soy products, that has been investigated as an anticancer agent and which behaves as an antioxidant.
Humanetics overview
Humanetics is a clinical-stage pharmaceutical company that develops and discovers proprietary products. The company provides medical foods, prescription drugs, and consumer products. It offers a radiomodulator development program that includes BIO 300, which is used in cancer patients to reduce the side effects of radiation treatments. Humanetics also undertakes clinical trial for INDs for BIO 300. The company discovers and develops products in the areas of medical imaging, oncology, and medical countermeasures. It collaborates with private and public research institutions for its research activities. Humanetics is headquartered in Minneapolis, Minnesota, the US.
For a complete picture of Genistein’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
